Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Koanewa: A First in Human, Phase 1b, Open-label, Non-randomised, Single Dose Study to Assess the Safety and Tolerability of CTx1000 in Participants Diagnosed With Amyotrophic Lateral Sclerosis

NCT07401121 is registered in ClinicalTrials.gov with Celosia Therapeutics Pty Ltd as lead sponsor.

NCT NCT07401121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07401121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Koanewa: A First in Human, Phase 1b, Open-label, Non-randomised, Single Dose Study to Assess the Safety and Tolerability of CTx1000 in Participants Diagnosed With Amyotrophic Lateral Sclerosis
Lead sponsor
Celosia Therapeutics Pty Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
January 12, 2026
Completion date
December 31, 2030
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

als (amyotrophic lateral sclerosis)